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ABSTRACT 
The treatment planning process for patients with head and neck (H&N) cancer is regarded 
as one of the most complicated due to large target volume, multiple prescription dose levels, 
and many radiation-sensitive critical structures near the target. Treatment planning for this 
site requires a high level of human expertise and a tremendous amount of effort to produce 
personalized high quality plans, taking as long as a week, which deteriorates the chances of 
tumor control and patient survival. To solve this problem, we propose to investigate a deep 
learning-based dose prediction model, Hierarchically Densely Connected U-net, based on 
two highly popular network architectures: U-net and DenseNet. We find that this new 
architecture is able to accurately and efficiently predict the dose distribution, outperforming 
the other two models, the Standard U-net and DenseNet, in homogeneity, dose conformity, 
and dose coverage on the test data. Averaging across all organs at risk, our proposed model 
is capable of predicting the organ-at-risk max dose within 6.3% and mean dose within 5.1% 
of the prescription dose on the test data. The other models, the Standard U-net and DenseNet, 
performed worse, having an averaged organ-at-risk max dose prediction error of 8.2% and 
9.3%, respectively, and averaged mean dose prediction error of 6.4% and 6.8%, respectively. 
In addition, our proposed model used 12 times less trainable parameters than the Standard 
U-net, and predicted the patient dose 4 times faster than DenseNet. 
  
I. INTRODUCTION 
Patients with head and neck (H&N) cancer undergoing radiotherapy have typically been 
treated with intensity modulated radiation therapy (IMRT)1-7 and volume modulated arc 
therapy (VMAT)8-15, which has significantly reduced toxicity16-18 and improved quality of 
life19,20, as compared to more conventional methods such as 3D conformal radiotherapy. 
However, treatment planning for this site is regarded as one of the most complicated due to 
several aspects, including large planning target volume (PTV) size21, multiple prescription 
dose levels that are simultaneously integrated boosted22,23, and many radiation-sensitive 
organs-at-risk (OAR) that are in close proximity to the PTV24-27. Consequently, treatment 
planning for this site requires a tremendous level of human expertise and effort to produce 
personalized high quality plans. 
In the typical current treatment planning workflow, a treatment planner solves an inverse 
optimization problem28, where they adjust a set of hyper-parameters and weightings to 
control the tradeoffs between clinical objectives. Since the physician preferred plan is largely 
unknown, the planner meticulously tunes these parameters in a trial-and-error fashion in an 
attempt to reach an appropriate solution. Many rounds of consultation between the planner 
and physician occur regarding the plan quality and tradeoffs are discussed. Ultimately, this 
trial-and-error process in parameter tuning results in hours for a plan to be generated29-31, 
and the iterations of consultation between the physician and planner may extend the 
treatment planning time up to one week. For aggressive H&N tumors, where tumor volume 
can double in approximately 30 days, which account for 50% of patients32, an extended 
planning time can greatly decrease local tumor control and patient survival33-36. 
In recent years, the field of artificial intelligence (AI) and deep learning has made 
tremendous progress, particularly in the field of computer vision and decision making. In 
2015, Ronneberger et al. proposed a deep learning architecture for semantic segmentation, 
known as U-net37. This neural network architecture, a type of convolutional neural network 
(CNN)38 that falls under the class fully convolutional networks (FCN)39, was capable of 
incorporating both local and global features to make a pixel-wise prediction. These 
predictions are commonly done slice-by-slice in 2D. For dose prediction, this 2D-based 
prediction can inherently cause some errors, particularly in slices at the superior and 
inferior edges of the PTV, thus motivating us to move towards 3D volumetric deep learning 
models.  However, when creating a 3D variant of U-net, the computational expense grows 
with the dimensionality. Tradeoffs have to be made with the 3D version, such as less filters 
per convolution or max pooling layers.  Attempts to combat this for 3D architectures focused 
on modifying portions of the architecture to be more efficient at propagating information, 
such as having a ResNet flavor of including skip connections during each block40,41. With the 
currently available GPU technologies and memory, the network’s performance is sacrificed. 
A publication in 2017 by Huang et al. proposed a Densely Connected Convolutional Neural 
Network, also known as DenseNet 42. The publication proposed the novel idea of densely 
connecting its convolutional maps together to promote feature propagation and reuse, 
reduce the vanishing gradient issue, and decrease the number of trainable parameters 
needed. While the term “densely connected” was historically used to described fully 
connected neural network layers, this publication by Huang et al. had adopted this 
terminology to describe how his convolutional layers were connected. While requiring more 
memory to use, the authors showed that the DenseNet was capable of achieving a better 
performance while having far less parameters in the neural network. For example, they were 
able to have comparable accuracy with ResNet, which had 10 million parameters, using their 
DenseNet, which had 0.8M parameters. This indicates that DenseNet is far more efficient in 
feature calculation than existing network architectures. For its contribution to the AI 
community, the DenseNet publication was awarded for the CVPR 2017 best publication. 
However, it is recognized that DenseNet, while efficient in parameter usage, actually utilizes 
considerably more GPU RAM, rendering a 3D U-net with fully densely connected 
convolutional connections infeasible for today’s current GPU technologies.  
Motivated by a 3D densely connected U-net, but requiring less memory usage, we developed 
a neural network architecture that combines the essence of these two influential neural 
network architectures into our proposed network while maintaining a respectable RAM 
usage, which we call Hierarchically Densely Connected U-net (HD U-net). The term 
“hierarchically” is used here to describe the different levels of resolution in the U-net 
between each max pooling or upsampling operation. The convolutional layers are densely 
connected along each hierarchy, but not between hierarchies of the U-net during the 
upsampling operation. In particular, we wish to utilize the global and local information 
capabilities of U-net and the more efficient feature propagation and reuse of DenseNet. 
DenseNet alone is not expected to perform well for this task as we conjecture that the 
accurate prediction of dose distribution requires both global and local information. While 
the feature maps of DenseNet are connected throughout the network, which allows for an 
efficient feature propagation, the lack of pooling followed by subsequent upsampling 
procedure, that is found in U-net, limits the network’s capability to capture global 
information. In this study, we will assess the proposed deep learning architecture on its 
capability to volumetrically predict the dose distribution for patients with H&N cancer, and 
compare its performance against the two deep learning models from which it was inspired 
from: U-net and DenseNet. The HD U-net and the 3D variants of U-net and DenseNet can all 
fit on a 11GB 1080 Ti GPU for unbiased comparison.  
II. METHODS 
II.1. H&N Patient Data 
We acquired a total of 120 H&N patients for this study. Table 1 summarizes some of the 
patient information. The H&N cancer sites included base of tongue, lateral border of tongue, 
tonsillar fossa, glottis, supraglottis, thyroid, thyroid gland, larynx, mouth, mandible, pharynx, 
oropharynx, nasopharynx, hypopharynx, pyriform sinus, tonsil, retromolar area, parotid 
gland, bone, laryngeal cartilage, sublingual gland, nasal cavity, vallecula, aryepiglottic fold, 
lingual tonsil, maxillary sinus, laryngeal cartilage, parts of face, and trachea. The specific ICD 
codes of the patients used this study included C01, C09.0, 161.0, 193, C79.89, C32.9, C06.9, 
C32.8, 161.9, C12, C73, C09.8, C06.2, C07, 145.6, 161.1, C11.3, C79.51, C77.0, C32.3, C08.1, 
D10.6, C02.3, C11.1, C09.9, C49.0, 160.0, C10.0, C13.1, 141.6, C31.0, 147.9, C10.8, 161.3, 
C11.2, 141.0, 149.0, 141.2, 160.2, 146.0, 172.3, 146.9, C33, C13.2, C02.1, C32.1, C76.0, C41.1, 
C02.8, and C06.89 
 Min Median Mean Max 
Age (yr) 18 60 61.43 91 
Number of targets 1 3 2.94 5 
Prescription dose 
(Gy) 
42.5 60 61.51 72 
Total target 
volume (cc) 
38.75 700.06 706.73 1997.38 
Body volume (cc) 10602.68 14451.15 13229.69 37060.00 
Table 1: Summary of patient information 
For each patient, we obtained the structure contours and the clinically delivered VMAT dose, 
calculated on the Eclipse Treatment Planning System. The voxel resolution of both the 
contours and dose were set to 5 mm3.  As input, each OAR was set as separate binary masks, 
where each voxel is assigned 1 if the voxel is assigned to the OAR and 0 otherwise, in their 
own channel. The patient CT was not included as input for this study. The PTVs were 
included as their own channel, but instead of a binary mask, the mask was set to have a value 
equal the prescribed radiation dose. Each patient had 1-5 PTVs, with prescription doses 
ranging from 42.5 Gy to 72 Gy. In total, the input data used 23 channels to represent the 
OARs, PTVs, and prescription doses. Because we wished to input the prescription dose for 
the PTV’s in Gy and then output the resulting in dose distribution in Gy, we chose not to 
normalize the data. This means the prediction model will have to learn how to propagate the 
prescription information directly. The 22 OARs used in this study are the body, left and right 
brachial plexus, brain, brainstem, left and right cerebellum, left and right cochlea, 
constrictors, esophagus, larynx, mandible, left and right masseter, oral cavity, post arytenoid 
& cricoid space (PACS), left and right parotid, left and right submandibular gland (SMG), and 
spinal cord. In the case that the patient was missing one of the 22 OARs, the corresponding 
channel was set to 0 for the input.  
 
II.2. Deep Learning Terminology 
In this section, we will define the some of the core deep learning terminology used in this 
paper. Convolutional neural networks (CNN) were first proposed in by LeCun et al 43,44, and 
had quickly found their use in deep learning for computer vision and imaging tasks.  By using 
kernels and convolution, CNNs can easily extract image features, such as edges. Additionally, 
CNN feature extraction are shift invariant and use overall less weights than fully connected 
networks. Each convolution layer of a CNN calculates a set of feature maps from the input or 
a set of feature maps from the previous layer. DenseNet is a type of CNN, where the previous 
maps are concatenated to future layers. 
Activation functions are non-linear functions typically used after a convolutional or fully 
connected operation.  The Rectified Linear Unit (ReLU) 45 is one of today’s most popular 
types of activation functions. It is defined as 𝑓(𝑥) = max⁡(0, 𝑥). It gained popularity for its 
resulting great performance in models. It did not suffer from the vanishing gradient issues 
found in other activation functions, such as the sigmoid or tanh functions. Also, it was 
computationally cheap to perform, which helped further speed up the training of neural 
networks. 
Pooling in deep learning refers to dividing a feature map into rectangular patches, and then 
aggregating the pixel information in each patch to create a new, lower-resolution layer that 
retains important features of the high resolution map. Typically, the patches are 2 x 2 for 2D 
and 2 x 2 x 2 for 3D inputs with a stride of 2, which effectively halves each dimension on the 
output feature map. This greatly reduces the computational expense and helps the network 
see the image more globally while using a standard size convolution kernel. Max pooling 46, 
where from each rectangular patch, the single largest pixel value is carried over, became one 
of the most popular pooling methods to use with CNNs. There is no direct inverse operation 
to max pooling, but some common techniques to increase the resolution include upsampling 
and deconvolution 47. 
The loss or cost function is a term used in both machine learning and optimization, and is a 
function that quantifies a particular state into a single value. The goal is to minimize or 
maximize this value by changing a set of defined parameters in the problem. For deep 
learning, the network is parameterized by a large number of weights, and the loss, for 
supervised learning, is typically defined as some type of error between the neural network’s 
prediction and a known ground truth. By being fed many examples, the network’s weights 
are tuned to minimize this error. Some very common loss functions used in deep learning 
today are mean squared error and cross entropy. 
 
 
 
 
II.3. Deep Learning Architectures 
 
 
 
Figure 1: Architectures used within the study. Black numbers on the left side of the model 
represent the volume shape and resolution at a specific hierarchy. Red numbers represent 
the number of feature maps at a particular layer. Orange features represent the newly 
calculated features, and trainable parameters to learn, while blue features are copied or 
max pooled features that do not need trainable parameters. 
Figure 1 shows all of the specific architectures that were used in the study. The HD U-net 
utilizes 3 operations defined in the legend: dense convolve, dense downsample and U-net 
upsample. The dense convolve effectively uses a standard convolution with ReLU, followed 
by a concatenation of the previous feature set. Performing this operation back-to-back is 
equivalent to the densely connected computation in the DenseNet publication. The dense 
downsampling operation is performed by a strided convolution and ReLU to calculate a new 
feature set that has half the resolution. The previous feature set is then max pooled and 
concatenated to the new feature set. Lastly, the U-net upsampling operation is done by up-
sampling, convolution, and ReLU, followed by a concatenation of the feature set on the other 
side of the “U”. This “u-net upsampling” is the same operation used in the standard U-net, 
with the upsample + convolve sometimes replaced with the transposed convolution. For 
each dense operation, a growth rate can be defined as the number new features calculated 
during the convolution step. Specifically, we utilized a growth rate of 16 (16 new features 
added after each “dense” operation), 4 dense downsampling operations, and 64 features 
returned during the upsampling operation. 
To assess the performance of our implementation, our Hierarchically Dense (HD) U-net is 
compared to the two models which had inspired its design: the standard U-net and DenseNet. 
To fairly assess the architectures, the standard U-net, was constructed to match the HD U-
net in terms of the number of downsampling operations used, and followed the conventional 
build of U-net, where the number of filters are doubled after each max pooling operation. It 
utilizes the regular convolution and max pooling, as defined in the green arrows in the legend 
in Figure 1. 
DenseNet was constructed as outlined in the DenseNet publication, with dense-blocks 
followed by compression layers. Since DenseNet has an entirely different architecture than 
the U-nets, we simply chose to match the number of trainable parameters to HD U-net as 
close as possible. Ultimately, to meet this number of parameters, we chose to have 7 dense 
blocks, 5 dense convolutions per dense block, and a compression factor of 0.5. DenseNet 
utilizes the dense convolution during the dense block, and a normal convolution that reduces 
the number of layers by our set compression factor. 
All networks were constructed to use 3D operations to handle the volumetric H&N data. 
After determining that overfitting was not occurring, based on the training the validation 
loss curves shown in Figure 2, it was decided that dropout, L1 regularization, and L2 
regularization will not be used in the final model. Batch normalization was briefly tested, but 
after some trial-and-error testing, it was ultimately removed in the final models. Exact details 
of each network is summarized in the appendix. 
 
II.4. Training and Evaluation 
Of the 120 H&N patients, we set aside 20 patients as testing data to evaluate at the end. To 
assess the performance and stability of each model—HD U-net, Standard U-net, and 
DenseNet—a 5-fold cross validation procedure was performed on the remaining 100 
patients, where, for each fold, the patients were divided into 80 training patients and 20 
validation patients. During each fold, the model would have its weights randomly initialized, 
and then update its weights based on the training set. The validation loss is used to 
determine the iteration that had the best model weights, a well-known method to help 
prevent from obtaining a model that has overfitted to the data48,49. This instance of the model 
is then used to evaluate the validation data. After all models from every fold was trained, the 
models then evaluated the testing data, and the results combined and averaged through 
bootstrap aggregation (bagging) 50 without replacement 51. Bagging an ensemble of 
predictors helps improve the stability and accuracy of the algorithm, and aids in preventing 
overfitting. 
Mean squared error between the predicted dose and the clinically delivered dose was used 
as the loss function for training each neural network model.  The learning rate of each model 
was adjusted to minimize the validation loss as a function of epochs. The patch size used for 
neural training was 96 x 96 x 64. Matching the U-net paper37, we used a batch size of 1 
sample. Instead of subdividing the patient contours and their corresponding dose volumes 
into set patches, each iteration of the model training process randomly selected a patch from 
the patient volume on-the-fly. Random patch selection also inherently adds stochastic 
translational shifts into the training data, which is one of the basic forms of data 
augmentation. While not the most robust data augmentation, this helps to somewhat reduce 
the overfitting issue, particularly for small datasets. 
To equally compare across the patients, all plans were normalized such that the PTV with 
the highest corresponding prescription dose had 95% of its volume receiving 100% of the 
prescription dose (𝐷95). All dose statistics will also be reported relative to the prescription 
dose (i.e. the errors are reported as a percent of the prescription dose). As evaluation criteria 
PTV coverage (D98, D99), PTV max dose, homogeneity (
𝐷2−𝐷98
𝐷50
), van’t Riet conformation 
number52 (
(𝑉𝑃𝑇𝑉⁡∩⁡𝑉100%𝐼𝑠𝑜)
2
𝑉𝑃𝑇𝑉⁡×⁡𝑉100%𝐼𝑠𝑜
) , and the structure max and mean doses (Dmax and Dmean) were 
evaluated. 
To maintain consistency in performance, all neural network models were trained and 
evaluated on an NVIDIA GTX 1080 Ti GPU with 11 GB dedicated RAM.  
III. RESULTS 
 
Figure 2: Mean loss across the 5 cross-validation folds for each model. The error equals 1 
standard deviation. 
Figure 2 shows the mean training and validation loss for the HD U-net, Standard U-net, and 
DenseNet. The HD and Standard U-net have a similar training loss as a function of epochs. 
However, the validation loss of the HD U-net is much lower and has less variation between 
the folds of the cross validation than that of the Standard U-net. This indicates that HD U-net 
is better at generalizing the modeling contours-to-dose, and is overfitting less to the training 
data. The DenseNet performed the worst for both the mean training and validation loss, as 
well as having the largest variation in the validation loss. 
 
 
Trainable 
parameters 
Training Time 
(s) (averaged 
across cross 
validation folds) 
Mean ± SD 
Prediction time for 
entire patient volume 
(s) 
Mean ± SD 
Test Cross-Val 
HD U-net 3,289,006 11138.4 ± 50.6 5.42 ± 1.99 5.39 ± 2.39 
Standard U-net 40,068,385 8688.0 ± 50.2 4.48 ± 1.67 4.60 ± 2.01 
DenseNet 3,361,708 31764.0 ±  53.7 
17.12 ± 
6.42 
18.05 ± 
7.97 
Table 2: Trainable parameters and prediction time for each model. 
Table 2 shows the number of trainable parameters and the prediction time for each model 
used in the study. The HD U-net and DenseNet have approximately 12 times less trainable 
parameters than the Standard U-net. The training time of HD U-net was about 3 hours, which 
is slightly longer than the Standard U-net’s time of 2.4 hours. DenseNet had the longest 
training time of 8.8 hours. The prediction time of the HD U-net is approximately 1 second 
longer for a full patient prediction, using patches of 96 x 96 x 64 and stride of 48 x 48 x 32. 
DenseNet had the longest prediction time of about 4 times longer than either of the U-nets. 
 
PTV dose coverage and max dose 
Average values (
1
𝑛
∑
𝑉𝑎𝑙𝑢𝑒𝑖
𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑝𝑡𝑖𝑜𝑛⁡𝐷𝑜𝑠𝑒𝑖
𝑛
𝑖=1 ) 
 
D95 D98 D99 Dmax 
Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
Test 
Results 
Ground 
Truth 
0.9999 ± 0.0002 0.99 ± 0.02 0.97 ± 0.03 1.04 ± 0.02 
HD U-net 0.9999 ± 0.0005 0.99 ± 0.01 0.97 ± 0.02 1.07 ± 0.02 
Standard 
U-net 
1.0000 ± 0.0006 0.98 ± 0.02 0.96 ± 0.03 1.11 ± 0.03 
DenseNet 0.9900 ± 0.0993 0.97 ± 0.10 0.96 ± 0.11 1.11 ± 0.16 
Cross-
Validation 
Results 
Ground 
Truth 
1.0002 ± 0.0003 0.96 ± 0.07 0.91 ± 0.17 1.06 ± 0.04 
HD U-net 1.0001 ± 0.0004 0.98 ± 0.03 0.94 ± 0.11 1.08 ± 0.03 
Standard 
U-net 
0.9999 ± 0.0005 0.98 ± 0.01 0.95 ± 0.14 1.13 ± 0.04 
DenseNet 1.0001 ± 0.0004 0.98 ± 0.02 0.95 ± 0.11 1.09 ± 0.04 
Table 3: Average PTV coverage and max dose for the ground truth and the prediction 
models. 
 
PTV dose coverage and max dose 
Average percent prediction error (
1
𝑛
∑
|𝑇𝑟𝑢𝑡ℎ𝑖−𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑖𝑜𝑛𝑖|
𝑃𝑟𝑒𝑠𝑐𝑟𝑖𝑝𝑡𝑖𝑜𝑛⁡𝐷𝑜𝑠𝑒𝑖
𝑛
𝑖=1 × 100) 
 D95 D98 D99 Dmax 
Mean 
± SD 
p-val 
Mean 
± SD 
p-val 
Mean 
± SD 
p-val 
Mean 
± SD 
p-val 
Test 
Results 
HD U-net 
0.02 ± 
0.05 
— 
1.18 ± 
1.82 
— 
1.96 ± 
2.14 
— 
3.75 ± 
1.60 
— 
Standard 
U-net 
0.03 ± 
0.06 
0.261 
1.77 ± 
2.35 
0.001 
2.65 ± 
2.95 
0.006 
7.42 ± 
3.26 
2.54 x 
10-17 
DenseNet 
1.01 ± 
9.93 
0.322 
2.45 ± 
10.13 
0.207 
3.42 ± 
10.39 
0.148 
7.26 ± 
15.37 
0.026 
HD U-net 
0.02 ± 
0.05 
— 
2.69 ± 
6.13 
— 
6.02 ± 
12.94 
— 
3.84 ± 
3.13 
— 
Cross-
Validation 
Results 
Standard 
U-net 
0.03 ± 
0.06 
0.365 
2.86 ± 
6.50 
0.423 
5.50 ± 
9.69 
0.651 
7.64 ± 
4.33 
1.01 x 
10-12 
DenseNet 
0.03 ± 
0.06 
0.087 
2.82 ± 
6.32 
0.473 
6.41 ± 
13.59 
0.259 
5.02 ± 
3.98 
1.20 x 
10-4 
Table 4: PTV coverage and max dose prediction errors for each model. The p-values < 0.05 
signify the statistical significance of the difference in the errors of the predictions of HD U-
net against the Standard U-net and DenseNet. 
 
Homogeneity and van’t Riet conformation number 
Average values (
1
𝑛
∑ 𝑉𝑎𝑙𝑢𝑒𝑖
𝑛
𝑖=1 ) 
 
Homogeneity (
𝐷2−𝐷98
𝐷50
) 
van’t Riet conformation 
number 
Mean ± SD Mean ± SD 
Test 
Results 
 
Ground Truth 0.06 ± 0.04 0.78 ± 0.06 
HD U-net 0.08 ± 0.02 0.76 ± 0.06 
Standard U-net 0.13 ± 0.04 0.74 ± 0.07 
DenseNet 0.12 ± 0.18 0.74 ± 0.12 
Cross-
Validation 
Results 
Ground Truth 0.09 ± 0.09 0.74  ± 0.09 
HD U-net 0.10 ± 0.05 0.73 ± 0.08 
Standard U-net 0.14 ± 0.04 0.73  ± 0.08 
DenseNet 0.10 ± 0.04 0.74  ± 0.07 
Table 5: Average homogeneity and van’t Riet conformation numbers for the ground truth 
and the prediction models. 
 
Homogeneity and van’t Riet conformation number 
Average percent prediction error  (
1
𝑛
∑
|𝑇𝑟𝑢𝑡ℎ𝑖−𝑃𝑟𝑒𝑑𝑖𝑐𝑡𝑖𝑜𝑛𝑖|
1
𝑛
𝑖=1 × 100) 
 
Homogeneity (
𝐷2−𝐷98
𝐷50
) 
van’t Riet conformation 
number 
Mean ± SD p-val Mean ± SD p-val 
Test Results 
HD U-net 3.74 ± 1.78 — 3.08 ± 2.30 — 
Standard 
U-net 
7.39 ± 3.99 1.20 x 10-3 4.73 ± 4.30 3.37 x 10-9 
DenseNet 7.05 ± 17.39 0.063 6.28 ± 10.56 0.029 
HD U-net 5.25 ± 6.76 — 4.84 ± 4.08 — 
Cross-
Validation 
Results 
Standard 
U-net 
8.10 ± 6.04 3.09 x 10-7 6.12 ± 5.73 0.307 
DenseNet 6.11 ± 6.90 0.004 6.70 ± 5.21 0.357 
Table 6: Homogeneity and van’t Riet conformation number prediction errors, taken as a 
percentage of the maximum of its achievable range. In our case, both homogeneity and the 
conformation number are defined to range from 0 to 1. The p-values < 0.05 signify the 
statistical significance of the difference in the errors of the predictions of HD U-net against 
the Standard U-net and DenseNet. 
 
Table 3 shows the average values of the PTV coverage and max dose of the ground truth dose 
and the predicted clinical dose, and Table 4 shows the percent errors in the models’ 
prediction on PTV coverage and max dose. While the models had similar performance in D95, 
D98 and D99 for the cross-validation data, the HD U-net had statistically significantly better 
performance in predicting the dose coverage on the test set, as compared to that of Standard 
U-net. HD U-net also had significantly less error in predicting the maximum dose to the PTV, 
as compared to the other two networks. Table 5 reports the average homogeneity indices 
and the van’t Riet conformation numbers for the clinical dose and the predicted dose from 
the networks, and Table 6 shows the percent errors in the model’s prediction of homogeneity 
and van’t Riet conformation numbers. Statistically, the HD U-net’s prediction on the test set 
of data has significantly less error in homogeneity and conformation than that of the 
Standard U-net, as well as significantly less error in conformation that that of the DenseNet. 
In addition, for the cross validation, HD U-net prediction had significantly less error than the 
other two network’s predictions in homogeneity. 
 
 
Figure 3: Absolute Error of Dmax on the structures of interest. Error is reported as a 
percentage of the prescription dose. 
 
Figure 4: Absolute Error of Dmean on the structures of interest. Error is reported as a 
percentage of the prescription dose. 
Figure 3 and Figure 4 show the Dmax and Dmean absolute errors on all of the 22 structures and 
PTV. Due to the large variability in number of PTVs and prescription doses, percent errors 
are reported as a percent of the highest prescription dose for the patient, and the PTV Dmean 
and Dmax calculation for Figure 3 and Figure 4 used the union of all the plan’s PTVs as the 
region of interest. Normalization by the prescription dose allows for one to know how much 
error to expect given a prescription, and can decide if more attention to an OAR is needed. It 
can be easily seen that the HD U-net, shown in blue, has an overall lower prediction error on 
the Dmax and Dmean than the other two networks in this study. For the cross-validation data, 
the HD U-net, Standard U-net, and DenseNet predicted, on average, the Dmax within 6.23 ± 
1.94%, 8.11 ± 1.87%, and 7.65 ± 1.67%, respectively, and the Dmean within 5.30 ± 1.79%, 6.38 
± 2.01%, and 6.49 ± 1.43%, respectively, of the prescription dose.  For the test data, the 
models predicted Dmax within 6.30 ± 2.70%, 8.21 ± 2.87%, and 9.30 ± 3.44%, respectively, 
and Dmean within 5.05 ± 2.13%, 6.40 ± 2.63%, and 6.83 ± 2.27%, respectively, or the 
prescription dose. Overall, the HD U-net had the best performance on both the cross-
validation and test data. DenseNet had the largest discrepancy between its performance on 
the cross-validation data and test data, indicating its prediction volatility on data outside of 
its training and validation set. 
 
Figure 5: Dose volume histogram of an example patient from the test pool.  
Figure 5 shows an example DVH from a patients from the test data. The solid line with the 
lighter color variant represents the clinical ground truth dose, while the darker color 
variants represent the predicted dose from HD U-net (solid), Standard U-net (dashed), and 
DenseNet (dotted). For this example patient, the HD U-net is superior to the other models in 
predicting the dose to the PTVs. Prediction of OAR dose are more variable between the 
models. This is also reflected in Figure 3 and Figure 4, where the standard deviation in 
prediction is small for the PTVs using the HD U-net, and larger on the OAR Dmax and Dmean 
prediction.  
 
Figure 6: Dose washes of example patient from the test pool. The color bar is shown in units 
of Gy. The clinical ground truth dose is shown on the top row, followed by the dose 
predictions of the HD U-net, Standard U-net, and DenseNet, respectively. Low dose cutoff for 
viewing was chosen to be 5% of the highest prescription dose (3.5 Gy). 
Figure 6 shows the dose color wash for the same patient in Figure 5. Visually, the dose 
prediction models have comparable dose to the PTVs, with the Standard U-net and DenseNet 
slightly hotter than the HD U-net. The DenseNet also predicts dose above 3.5 Gy everywhere 
in the body, which is also reflected in the DVH in Figure 5 (purple dotted line) and the dose 
wash in Figure 6. The back of the neck is predicted to have more dose by all of the models, as 
compared to ground truth, which may represent a lack of data representation in the training 
data, or a lack of information being fed into the deep learning model itself. 
 
IV. DISCUSSION 
To our knowledge, this is the first instance of an accurate volumetric dose prediction for H&N 
cancer patients treated with VMAT. Existing plan prediction models are largely based around 
Knowledge Based Planning (KBP)53-66, with clinical/commercial implementations available 
known as Varian RapidPlan (Varian Medical Systems, Palo Alto, CA) and Pinnacle Auto-
Planning Software (Philips Radiation Oncology Systems). These KBP methods have 
historically been designed to predict the DVH of a given patient, instead of the full volumetric 
dose prediction. The only exception is the study by Shiraishi and Moore58 in 2016, where 
they perform 3D dose prediction. However, their study is currently only evaluated on 
prostate patients, and thus the results are not comparable to our results for H&N patients. A 
study by Tol et al. 67 that evaluated RapidPlan on H&N cancer patients, had found that, in one 
of their evaluation groups, RapidPlan, had a mean prediction error of as large as 5.5 Gy on 
the submandibular gland, with the highest error on a single patient’s OAR as high as 21.7 Gy 
on the lower larynx. Since their patients were clinically treated from 54.25 to 58.15 Gy, this 
translates to roughly 10% and 40% error, respectively in predictive performance. Another 
study by Krayenbuehl et al.68 had used Pinnacle Auto-Planning Software. However, in this 
study, the plan prediction aspect of the software was hidden from the user, and simply used 
as part of the auto-planning software itself, making this study’s methodology not directly 
comparable to ours. 
As a future study, we intend to perform a comprehensive evaluation and comparison of our 
dose prediction model against Varian RapidPlan. RapidPlan analyzes distance-to-target 
histograms—a relative geometrical relationship between an OAR and the PTV. In addition, 
RapidPlan incorporates relative overlap volume, relative out-of-field volume, absolute OAR 
volume, and absolute target volume69. Unlike our deep learning model, RapidPlan does not 
consider relationships between the OARs themselves, and thus does not account for 
tradeoffs between them. For an impartial comparison, both the RapidPlan and our dose 
prediction model must be trained and tested on the same data set. We plan to acquire a clean 
dataset that was used to train RapidPlan to accomplish an unbiased study. 
It is currently a challenge to directly compare against other non-commercial prediction 
models, particularly since they are developed in-house and are proprietary to the institution 
that developed it. It is typically infeasible to obtain a copy or to faithfully replicate it to the 
exact specifications that were used by the originators. In addition, training and evaluation of 
the model is usually performed using the institution’s own data, and is often unavailable to 
the public to replicate the results or to train their own model for an unbiased comparison. 
These are common issues in the era of data driven modeling for the field of medicine, and 
while efforts to develop large public datasets exist, we have yet to reach the point where it is 
commonplace to use communal datasets for apples-to-apples comparisons. 
Although the DenseNet had the poorest performance of the 3 models, it is due to the fact that 
the DenseNet is incapable of capturing global information into its prediction as the U-nets 
are capable of. This should not be seen as an oversight of DenseNet, as the authors of the 
paper proposed the concept of densely connected convolutional neural networks as a 
module, implying that this concept can be applied to more complex models. Their proposed 
DenseNet was used to illustrate the efficient feature propagation and reuse, alleviate the 
vanishing gradient, and reduce the number of parameters to moderate the overfitting issue. 
While DenseNet also had the slowest training and prediction time, it is possible that this 
issue may be alleviated with the newer GPUs, that are designed specifically for deep learning, 
such as the Volta architecture with tensor cores. 
While CT information was not used as an input, the ground truth clinical plan doses were 
calculated using the Eclipse dose calculation engine, which does account for CT information 
for the inhomogeneity correction. Since we are training the neural network to learn to 
predict this particular dose from just contours, the deep neural network may learn the 
correction itself without the need of the CT information. We plan to fully evaluate the effects 
of adding the CT as an additional input into the model in a future study. 
While accuracy tends to be positively correlated to a specific number of parameters in neural 
networks, the relationship is still not entirely clear between the accuracy and number of 
parameters, since neural networks are highly non-linear functions. Prediction time also 
tends to increase with more parameters and higher memory utilization, but is also affected 
by the breadth and depth of the network. Given the same number of trainable parameters, a 
fatter network with less layers will tend to predict more quickly than a skinny network with 
many layers, since the GPU can take advantage of the parallel computation. 
The current main disadvantage of the densely connected architecture is that it requires a 
much larger memory usage, per trainable parameter, than standard networks. This is 
because it carries many of the past features it has calculated in memory in order to compute 
the next feature map. Xiaomeng et al. previously attempted to combat this with a hybrid 
densely connected U-net, where they combine a 2D Dense U-net, to extract intra-slice 
features, with a 3D counterpart for aggregating volumetric contexts70. However, on a 12 GB 
RAM Titan Xp, the number of input slices they used at a time is 12, with feature maps 
containing only 3 slices during the dense block calculation. For radiotherapy, we require a 
much larger number of slices (e.g. 64) to make an accurate dose prediction, particularly for 
a complex site such as H&N. This makes the hybrid dense U-net by Xiaomeng et al. infeasible 
to use since it no longer fits on a modern GPU, hence our motivation for a less RAM intensive 
version of a densely connected U-net. Even with the extra memory cost, the expense is offset 
by the exceptionally efficient feature calculation. The Standard U-net, while capable of 
utilizing both the local and global information into its prediction still has considerable 
prediction error, indicating that either the model is not intelligent enough for the task, or it 
is not using its trainable parameters efficiently enough. In this study, we have shown, that by 
constructing a U-net with densely connected properties, we can take advantage of both U-
net and DenseNet in our proposed model, and we are capable of reducing the total number 
of trainable parameters by 12 fold while attaining a superior prediction result, as compared 
to the Standard U-net. 
There are currently several limitations to the study and the resulting model. One apparent 
limitation is the data size. Typical deep learning algorithms use considerably larger datasets 
in the hundreds of thousands or millions if needed. While we did not observe overfitting 
issues in the training and validation curves, possibly due to the fully convolutional nature of 
the U-net architecture and the relatively tight scope of the project goal, having substantially 
larger dataset may further tighten the generalization gap (the gap between the training and 
validation loss), and improve predictive performance. Another limitation is the inflexibility 
of the model with respect to adding more OARs. We trained the model to have the PTVs and 
22 specific structures as input. While the model can handle dose prediction on patients that 
are lacking some of the 22 structures, there is not a way for the model to account for other 
structures without entirely retraining the model. 
This dose prediction tool can currently be used as a clinical guidance tool, where the final 
tradeoff decisions and deliverable plan will still be made by the physician and dosimetrist. 
The amount of prediction error of the model can be used alongside the prediction during 
clinical guidance. As an average between all OARs, the HD U-net model can predict the OAR 
Dmax and Dmean within 6.3% and 5.1% of the prescription dose. It is quite possible that the 
model predicts for the dose of a particular OAR to be within absolute constraints, but is 
unachievable when the treatment plan is created. If the difference between the predicted 
values and the constraint is within the prediction error, the OARs of interested can be 
highlighted to be focused on during the treatment planning phase. 
We plan to expand on this study and improve the model in several ways. First, to further 
reduce the prediction error to the OARs, we plan to incorporate the dose constraints, as 
prescribed by the physician, an input into the prediction model. Furthermore, we will 
examine the addition and effects of the CT image as input on the prediction accuracy.  We 
expect that the addition of these types of information will prominently improve the deep 
learning model’s performance, and will investigate to quantify their impact. In addition, we 
plan to develop and integrate a dose mimicking optimization 71 to convert our predicted dose 
into the best machine parameters to deliver the plan.  As the field of artificial intelligence and 
deep learning continues to explosively progress, we will persistently investigate new deep 
learning concepts and architectures for more intelligent and efficient models to use. 
Eventually, our goal is to transition away from dose prediction based on historical plans to 
an AI-based treatment planning system, where we can push radiotherapy plans to improve 
and become better than that from current or past clinical practices. 
 
V. CONCLUSION 
We have developed and proposed a hierarchically densely connected U-net architecture, HD 
U-net, and applied the model to volumetric dose prediction for patients with H&N cancer. 
Using our proposed implementation, we are capable of accurately predicting the dose 
distribution from the PTV and OAR contours, and the prescription dose. On average, our 
proposed model is capable of predicting the OAR max dose within 6.3% and mean dose 
within 5.1% of the prescription dose on the test data. The other models, the Standard U-net 
and DenseNet, performed worse, having an OAR max dose prediction error of 8.2% and 
9.3%, respectively, and mean dose prediction error of 6.4% and 6.8%, respectively. HD U-
net also outperformed the other two models in homogeneity, dose conformity, and dose 
coverage on the test data. In addition, the proposed model is capable of using 12 times less 
trainable parameters than the Standard U-net, and predicted the patient dose 4 times faster 
than DenseNet. We plan to continue improving the model by incorporating more dose 
constraints and evaluating the addition of other data, such as the patient CT, on the model’s 
predictive performance. Our long-term goal is the development of an artificially intelligence-
based radiotherapy planning system. 
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APPENDIX 
A.1. Details on deep learning architectures used in study 
 HD U-net Standard U-net DenseNet 
Layer 
number 
Layer type Number  
features / 
channels 
Layer type Number 
features / 
channels 
Layer type Number 
features / 
channels 
       
1 Input 23 Input 23 Input 23 
2 Dense Conv 39 Conv 32 Dense Conv 47 
3 Dense Conv 55 Conv 32 Dense Conv 71 
4 Dense 
Downsample 
71 Max Pooling 32 Dense Conv 95 
5 Dense Conv 87 Conv 64 Dense Conv 119 
6 Dense Conv 103 Conv 64 Dense Conv 143 
7 Dense 
Downsample 
119 Max Pooling 64 Conv 72 
8 Dense Conv 135 Conv 128 Dense Conv 96 
9 Dense Conv 151 Conv 128 Dense Conv 120 
10 Dense 
Downsample 
167 Max Pooling 128 Dense Conv 144 
11 Dense Conv 183 Conv 256 Dense Conv 168 
12 Dense Conv 199 Conv 256 Dense Conv 192 
13 Dense 
Downsample 
215 Max Pooling 256 Conv 96 
14 Dense Conv 231 Conv 512 Dense Conv 120 
15 Dense Conv 247 Conv 512 Dense Conv 144 
16 Dense Conv 263 Conv 512 Dense Conv 168 
17 Dense Conv 279 Conv 512 Dense Conv 192 
18 U-net 
Upsample 
263 U-net 
Upsample 
512 Dense Conv 216 
19 Dense Conv 279 Conv 256 Conv  108 
20 Dense Conv 295 Conv 256 Dense Conv 132 
21 U-net 
Upsample 
215 U-net 
Upsample 
256 Dense Conv 156 
22 Dense Conv 231 Conv 128 Dense Conv 180 
23 Dense Conv 247 Conv 128 Dense Conv 204 
24 U-net 
Upsample 
167 U-net 
Upsample 
128 Dense Conv 228 
25 Dense Conv 183 Conv 64 Conv  114 
26 Dense Conv 199 Conv 64 Dense Conv 138 
27 U-net 
Upsample 
119 U-net 
Upsample 
64 Dense Conv 162 
28 Dense Conv 135 Conv 32 Dense Conv 186 
29 Dense Conv 151 Conv 32 Dense Conv 210 
30 Conv 1 Conv 1 Dense Conv 234 
31     Conv  117 
32     Dense Conv 141 
33     Dense Conv 165 
34     Dense Conv 189 
35     Dense Conv 213 
36     Dense Conv 237 
37     Conv  119 
38     Dense Conv 143 
39     Dense Conv 167 
40     Dense Conv 191 
41     Dense Conv 215 
42     Dense Conv 239 
43     Conv  120 
44     Conv 1 
Table 7: Details of deep learning architectures. Dense Conv and U-net Upsample follow the 
notation outlined in Figure 1. All convolutions mentioned in this table use 3 x 3 x 3 kernels 
and are followed by the ReLU non-linear activation. 
